Research Documents

• Treatment with Metalloproteinase Inhibitor XL784 Prevents the Development of Glomerulosclerosis in Dahl SS Hypertensive rat
• The T2DN Rat
• A Rat Test Population For Predicting Drug Toxicity
• Enhanced learning and behavioral adaptation in the FHH.BN1 consomic rat
• Using PharmGenix™ Rats to Detect Tacrine Hepatotoxicity
• Diabetes Induced Nephropathy In The T2DN Rat
• Impaired Learning and Behavioral Adaptation in the SSBN.13 Consomic Rat
• Drug toxicity signatures for acetaminophen using the PharmGenix panel of rats
• Drug Development Abstract Neuroscience 2008
• Preservation Abstract Neuroscience 2008
• Angiogenesis Abstract Neuroscience 2008

Our Intellectual Property

A portion of our competitive advantage rests on a unique combination of patent and patent pending Intellectual Property (IP) coupled with trade-secret know-how. We have licensed exclusive rights to the patent applications covering the T2DN rat and the PharmGenix combinatorial rat panel from the Medical College of Wisconsin.

PharmGenix:

Methods and Compositions for Pharmacological and Toxicological Evaluation of Test Agents (U.S. Provisional Patent Application No. 60/361,890, filed March 5, 2002, full patent filed March 2003). This invention relates to the methods for adding genetic diversity using combinatorial breeding of rodents to test the effects of drugs, chemicals and food ingredients. The method can save considerable time and money by improving the accuracy of safety testing. It also provides a method for determining the genetic basis of susceptibility or resistance to the actions of drugs and chemicals. Divisional patent applications are planned to apply the combinatorial testing approach to lower organism, agriculture and cell-based assays.

T2DNmimic:

A rat model of human diabetic nephropathy (U.S. Provisional Patent Application No. 60/398,446 filed July 25, 2002, full patent filed, July 2003). This invention covers the method used to genetically engineer the first diabetic rodent model that develops progressive diabetic nephropathy and renal lesions that resemble those seen in humans. We believe this rat strain has great utility as a model system for testing compounds for the treatment of diabetic nephropathy and other complications of diabetes such as diabetic retinopathy, vascular disease, cardiac ischemia, stroke and peripheral neuropathy. We utilize this strain to identify the genetic basis of diabetic nephropathy and diabetes. Any genes that are identified may be patentable as new drug targets and diagnostic tests. We also enjoy additional protection for this strain due to the fact that no other party (except its licensor) has physical possession of T2DN animals.